Purple Biotech granted new U.S. patent for NT219

Purple Biotech (PPBT) announced that the U.S. Patent and Trademark Office has issued a patent for NT219 used in combination with epidermal growth factor receptor, EGFR, antibodies for treating cancer patients who have acquired resistance to EGFR therapies. The patent, titled “Combinations of IRS/STAT3 dual modulators and anti-cancer agents for treating cancer” addresses NT219 in combination with cetuximab as well as other EGFR antibodies such as panitumumab and necitumumab in treating tumors resistant to EGFR therapy and in preventing or delaying cancer tumor recurrence following cessation of treatment with an EGFR therapy.